What Is in the Neuromuscular Junction Literature?
Journal
Journal of clinical neuromuscular disease
ISSN: 1537-1611
Titre abrégé: J Clin Neuromuscul Dis
Pays: United States
ID NLM: 100887391
Informations de publication
Date de publication:
01 Mar 2021
01 Mar 2021
Historique:
entrez:
17
2
2021
pubmed:
18
2
2021
medline:
26
2
2021
Statut:
ppublish
Résumé
This update covers recommendations for myasthenia gravis (MG) in patients with coronavirus 2019 disease as well as reports of the clinical features of patients with MG and coronavirus 2019. Updated advisory committee recommendations for the use of thymectomy in generalized MG are also provided. Other MG topics include lipoprotein receptor-4 and agrin antibody associations, factors influencing conversion of ocular to generalized MG, the use of rituximab for more recent onset disease, immunoglobulins for maintenance therapy, and fatigue and depression.
Identifiants
pubmed: 33595998
doi: 10.1097/CND.0000000000000345
pii: 00131402-202103000-00004
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
147-154Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
International MG/COVID-19 Working Group, Jacob S, Muppidi S, Guidon A, et al. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci. 2020;412:116803.
Sriwastava S, Tandon M, Kataria S, et al. New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review. J Neurol. 2020;12:1–7.
Camelo-Filho A, Silva A, Estephan E, et al. Myasthenia gravis and coivd-19: clinical characteristics and outcomes. Front Neurol. 2020;11:1053.
Restivo DA, Centonze D, Alesina A, et al. Myasthenia gravis associated with SARS-CoV-2 infection. Ann Intern Med. 2020;173:1027–1028.
Risitano AM, Mastellos DC, Huber-Lang M, et al. Complement as a target in COVID-19? Nat Rev Immunol. 2020;6:343–344.
Dalakas M. Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies. Curr Opin Neurol. 2020;33:545–552.
Anand P, Slama M, Kaku M, et al. COVID-19 in patients with myasthenia gravis. Muscle Nerve. 2020;62:254–271.
Muppidi S, Guptill J, Jacob S, et al. COVID-19- associated risks and effects in myasthenia gravis (Care-MG). Lancet Neurol. 2020;12:970–971.
Wolfe GI, Kaminski HJ, Aban IB, et al. On behalf of the MGTX study group. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016;375:511–522.
Gronseth G, Barohn R, Narauamaswami P, et al. Practice advisory: thymectomy for myasthenia gravis (practice parameter update). Neurol 2020;94:705–709.
Lee I, Juo HC, Aban B, et al. Minimal manifestation status and prednisone withdrawal in the MGTX trial. Neurol. 2020;95:755–766.
Narayanaswami P, Sanders DB, Gil W, et al. International consensus guidance for management of myasthenia gravis. 2020 update. Neurol. 2020;3:2020.
Li F, Li Z, Taahashi R, et al. Robotic-extended rethymectomy for refractory myasthenia gravis: a case series. Semin Thorac Surg. 2020;32:593–602.
Lee MC, Hsiao TH, Chuang HN, et al. Molecular profiling of thymoma with myasthenia gravis. Risk factors of developing myasthenia gravis in thymoma patients. Lung Cancer. 2020;139:157–164.
Rivner M, Quarles BM, Pan JX, et al. Clinical features of LRP4/agrin-antibody-positive myasthenia gravis. A multicenter study. Muscle Nerve. 2020;62:33–343.
Li F, Hotter B, Swierzy M, et al. Generalization after ocular onset in myasthenia gravis: a case series in Germany. J Neurol. 2018;265:2773–2782.
Hong YH, Kwon SB, Kim BJ, et al. Prognosis of ocular myasthenia in Korea: a retrospective multicenter analysis of 202 patients. J Neurol Sci. 2008;273:10–14.
Kupersmith MJ, Larkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol. 2003;60:243–248.
Apinyawasisuk S, Chongpison Y, Thitisaksakul C, et al. Factors affecting generalization of ocular myasthenia gravis in patients with positive acetylcholine receptor antibody. Am J Ophthalmol. 2020;209:10–17.
Hellmann MA, Mosberg-Galili R, Lotan I, et al. Maintenance IVIg therapy in myasthenia gravis does not affect disease activity. J Neurol Sci. 2014;338:39–42.
Alcantara M, Sarpong E, Barnett C, et al. Chronic immunoglobulin maintenance therapy in myasthenia gravis. Eur J Neurol. 2020;0:1–8.
Nowak RJ, Coffey C, Goldstein J. AAN 2018 Emerging science abstracts: B-cell targeted treatment in myasthenia gravis (BeatMG)- a phase 2 trial of rituximab in myasthenia gravis: topline results. Neurology. 2018;90:e2182–e2194.
A study evaluating the safety and efficacy of rituximab in patients with myasthenia gravis (Rinomax). ClinicalTrials.gov.Identifier:NCT02950155. Available at: https://clinicaltrials.gov/ct2/show/NCT02950155 . Accessed March 27, 2020.
Ruiter AM, Verschuuren JGM, Tanemaat MR. Fatigue in patients with myasthenia gravis. A systemic review of the literature. Neuromusc Dis. 2020;30:631–639.
Anderson H, Mantegazza R, Wang JJ, et al. Eculizumab improves fatigue in refractory generalized myasthenia gravis. Qual Life Res. 2019;28:2247–2254.
Gavrilov YV, Alekseeva TM, Kreis OA, et al. Depression in myasthenia gravis: a heterogeneous and intriguing entity. J Neurol. 2020;267:1802–1811.
Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–571.